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The activation of the CAMP signaling pathway by vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating peptide (PACAP) and 
related peptides was studied (i) in normal peripheral human monocytes and THP-1 leukemic human monocytes, (ii) in their derived macrophage 
counterparts respectively obtained after spontaneous differentiation or retinoic acid (RA) treatment, and (iii) in human bronchoalveolar macroph- 
ages. In THP-1 monocytes, PACAP increased basal adenylate cyclase activity 5.3-fold, with an affinity 50-times greater than that of VIP or 
helodermin (K, = 3.2 x lo-” M VIP), whereas in normal peripheral monocytes, PACAP and VIP exhibited similar affinities and only increased 
CAMP generation 2-fold (EC,, = 10m9 M). Spontaneous and RA-induced differentiation into normal and leukemic macrophages induced a 
progressive loss of CAMP production and regulation of superoxide anion production by VIP and related peptides. The neoplastic transformation 
in THP-1 monocytes and the deficiencies in the CAMP cascade observed during the terminal differentiation of normal and leukemic human 
macrophages may relate to a differential genetic expression of the VIP/PACAP receptor subtypes, and alterations in the functional activity of the 
stimulatory and inhibitory GJG, subunits of adenylate cyclase. 
Pituitary adenylate cyclase-activating peptide; Vasoactive intestinal peptide; Receptor; Monocyte; Macrophage; Leukemia 
1. INTRODUCTION 
Agents that raise CAMP levels inhibit T-lymphocyte- 
and natural killer cell-mediated cytotoxicity, as well as 
cytolytic functions and the chemotactic response. Evi- 
dence is accumulating that the neuropeptide vasoactive 
intestinal peptide (VIP) regulates the proliferation and 
immune responses of lymphocytes and monocytes [1,2]. 
Previous authors reported that the THP-1 monocytic 
leukemia cell line could be induced to undergo morpho- 
logical and functional maturation into macrophage-like 
cells by 12-O-tetradecanoylphorbol-13-acetate (TPA) 
and retinoic acid [3-51. Therefore, this cell line affords 
a useful model for studying the functional, pharmacol- 
ogical and genetic expression of receptor-mediated sig- 
nal transduction during monocytic differentiation. For 
this purpose, we investigated the interaction of VIP, 
pituitary adenylate cyclase activating peptide (PACAP) 
and related peptides (i) in THP-1 monocytes and their 
derived THP-1 macrophages obtained after differentia- 
tion by retinoic acid [5], (ii) in human bronchoalveolar 
macrophages, and (iii) in normal human peripheral 
monocytes and their differentiated macrophages coun- 
terparts. This study was also designed to investigate the 
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effect of VIP-related peptides and adenylate cyclase ac- 
tivators on the release of superoxide anions and Hz02 
formation in human bronchoalveolar macrophages and 
THP- 1 macrophages. The molecular basis for the induc- 
tion of the respiratory burst has not been as well charac- 
terized in macrophages as in neutrophils. In tissues and 
epithelia, macrophages can be activated to produce acti- 
vated oxygen species such as superoxide anion radicals 
0 i, peroxide 0; and hydroxyl radicals ‘OH. Hydrogen 
peroxide (H202) is formed by superoxide dismutation, 
then 0’; and H,O, interact to generate the highly reac- 
tive hydroxyl radical ‘OH. This respiratory burst and 
secretion of reactive oxygen intermediates play a funda- 
mental role in ischemia, inflammation and host defense 
by killing ingested microbes and invasive cancer cells 
[6]. Reactive oxygen species are produced by polymor- 
phonuclear granulocytes, monocytes, lymphocytes, me- 
sangial cells, platelets and fibroblasts. The direct activa- 
tors of PKC, phorbol esters, y-interferon, the chemo- 
tactic agent FMLP and platelet-activating factor (PAF) 
are known to initiate the respiratory burst in mononu- 
clear phagocytes. In contrast, CAMP and positive effec- 
tors of the adenylate cyclase system inhibit macrophage 
functions, including lysosomal enzyme release, migra- 
tion, phagocytosis and cytotoxicity. 
We began by comparing the action of the VIP-related 
peptides on CAMP generation and H20, formation in 
THP-1 cells with the effects produced by forskolin and 
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isoproterenol. Next, the specificity of the peptidergic 
action on CAMP production was similarly evaluated 
using a series of natural peptides structurally related to 
VIP, including PACAP- and its derivative PACAP- 
27, secretin, helodermin, helospectin I, the peptides with 
NH,-terminal histidine and C-terminal methionine 
(PHM-27), or with NH,-terminal histidine and C-termi- 
nal valine (PHV), human pancreatic growth hormone- 
releasing factor hpGRF 140, gastric inhibitory peptide 
(GIP). pancreatic glucagon. oxyntomodulin and glu- 
cagon-like peptide- (GLP-2). Part of this work has 
been published as an abstract [7]. 
2. EXPERIMENTAL 
2.1. Ceil culture and human alveolar macrophage collection 
THP-I cells originally obtained from Dr. T. Breitman (National 
Cancer Institute, Bethesda, MD, USA) have been maintained in our 
laboratory since 1982. They were grown m RPMI-1640 medium sup- 
plemented with 2 mM glutamide, 100 U/ml penicillin. 100 U/ml strep- 
tomycin and 10% fetal calf serum, at 37°C m an atmosphere of 5% 
CO?. The cells were routinely passaged every 3 or 4 days and seeded 
at a density of 2 x 10’ cells/ml. Cell viability was determined by the 
Trypan blue exclusion method. THP-1 cells differentiated after 4 days 
rn culture following the plating of 2 x 10’ cells/ml in the presence of 
5 x IO-’ M retinoic acid. added from a 10 mM stock solution m 
absolute ethanol. Differentiation was estimated by the percentage and 
absolute number of cells capable of reducing mtroblue tetrazohum 
(NBT) 151. 
Alveolar macrophages were obtained from bronchoalveolar lavages 
conducted under local anesthesia in 10 patients who underwent bron- 
choscopy for unilateral processes. For the lavage, 300 ml of normal 
saline was instilled in 50 ml aliquots via a bronchoscope into the right 
middle lobe or lingula of the lung contralateral to the lesion [S]. Only 
the last five aspirations were collected. The retrieved fluid was filtered 
over gauze to remove mucus, then centrifuged at 400 x g for 10 min 
at 4°C. The cells were washed 3 times by similar centrifugations and 
resuspensions in RPM1 1640 medium containing 30 mM NaHCO, and 
25 mM HEPES neutralized to pH 7.4. One ahquot of the recovered 
fluid was used for microbiologic and cytologic studies, includmg total 
and differential cell counts. after cytocentrifuge preparation. Alveolar 
macrophages were isolated by differential adherence. The washed cells 
were suspended in 35 mm Petri dishes at a concentration of 335 x 10’ 
cells per ml of the same RPM1 medium supplemented with 50 IUlml 
penicillin and 50 @ml streptomycin. The dishes were incubated for 
2 h at 37°C m a 95% an, 5% CO1 atmosphere to allow adherence of 
macrophages. Non-adherent leukocytes were removed by washing. 
Adherent cells were > 95% macrophages by typical morphological 
examination, and cell viability was > 95% as determined by Trypan 
blue exclusion. 
2.2. Preparation of human peripheral monocytes and mucrophuge actr- 
vutlon 
Human peripheral monocytes were isolated from normal volunteers 
and purified by leukapheresis and counter-current centrifugation 
elutriation. as previously described [9. IO]. Monocyte-derived macro- 
phages were induced at 37°C from purified fractions of human mon- 
ocytes cultured for 7 days in Iscove-modified Dulbecco buffer contain- 
ing 3 x 10m5 M /I-mercaptoethanol. 2 mM L-glutamme, 2 mM pyruvic 
acid, antibiotics and 2% human serum in a humidified atmosphere of 
5% CO, m air. 
2.3. Men&rune-bound udenylate cycluse preparatron and asscr) 
THP-I monocytes and retinoic acid-induced THP-1 macrophages 
were washed twice in chilled KRP buffer. The resulting cell pellet was 
suspended at a concentration of 20 x lo6 cells/ml of 10 mM Tris-HCI 
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buffer (pH 7.5) containing 1 mM EDTA, 30 mM NaCl and 5 PM 
phenylmethylsulfonyl fluoride [I 11. Cells were disrupted with a Poly- 
tron homogenizer (Kinematica, Luzern. Switzerland) using three 
bursts of 5 s each. The homogenate was centrifuged for 10 min at 
600 X g and 4°C in a Sorvall centrifuge RC-2 (Newton, CT). The 
supernatant was carefully drawn off by a Pasteur pipette and stored 
on ice. The pellets were resuspended by two strokes m 40 ml of 
homogenization buffer and centrifuged under the conditions described 
above. The two supernatants were then pooled and plasma membrane- 
enriched particles were obtained by differential centrifugation for 30 
min at 20,000 x g and 4°C. These fractions, used for the experiments 
on adenylate cyclase activity, will be subsequently referred to as 
plasma membranes. They were either used immediately or stored 
frozen at -80°C for less than 1 week. 
Adenylate cyclase activity was measured as previously described 
[l2]. Briefly, the standard incubation mixture (final volume: 250 ~1) 
contained: 1 mM ATP. 5 mM MgC12. the ATP-regenerating system 
(10 mM creatine phosphate and 0.5 mg/ml creatine kinase), 0.4 mM 
IBMX. 4 mg/ml BSA, 1 mM EGTA, 400 ,@ml bacitracin, 20 PM 
GTP, and test substances in 50 mM Tris-HCI buffer (pH 7.5). The 
reaction was initiated by the addition of membrane-bound adenylate 
cyclase (0.5-I pg membrane protein per tube) and the mixture was 
incubated for 15 min at 30°C. Cyclic AMP was determined by radi- 
oimmunoassay [12]. Data are expressed as nM CAMP produced per 
min per mg membrane protein. 
2.4. Cellular c:vchc AMP production 
Cyclic AMP generation was measured in human alveolar macroph- 
ages as adherent monolayers incubated for 30 mm at 20°C m 1 ml of 
35 mM Tris-HCI buffer (pH 7.5) containing 1 mM IBMX as a 
phosphodiesterase inhibitor, 1% BSA. and 50 mM NaCI. Purified 
peripheral human monocytes and their activated macrophage counter- 
parts were incubated under the same conditions. in a final volume of 
500 ~1. The reaction was stopped at the time indicated by adding I I 
N HCIO,. Cychc AMP was determined using a radioimmunoassay 
[l 11. Each experiment was performed m triplicate. 
2.5. Meusurement of H.0: production 
The production of H,OZ was measured m human bronchoalveolar 
macrophages and leukemic THP-1 macrophages, usmg the method 
described by Pick and Keisari. which is based on the HzO,-mediated 
and horseradish peroxidase-dependent oxidation of Phenol red [13]. 
The assay solution contained 140 mM NaCI. 10 mM potassium phos- 
phate buffer (pH 7.0). 5.5 mM glucose, 0.28 mM Phenol red and 8.5 
IU/ml horseradish peroxidase. About IO6 THP-1 macrophages were 
covered with 1 ml of the reaction solution containing 1 PM phorbol 
myristate acetate (PMA) and incubated for 60 min at 37°C in the 
presence or absence of the indicated effecters. Bronchoalveolar mac- 
rophages were incubated in the absence of PMA, since they exhibited 
a spontaneous release of superoxide anion Oz. At the end of incuba- 
tion, the culture medium was collected and centrifuged. The cell-free 
fluid was made alkaline by the addition of 10 ~1 of 1 N NaOH 
Absorbance was determined at 610 nm against a blank consistmg of 
the reaction solution supplemented with 10 ~1 NaOH. In control 
experiments. 1,250 IU/ml catalase was added to inhibit HzOz forma- 
tion. The cells were then scraped off their supports in Krebs-Ringer 
phosphate buffer and somcated for protein determination. The results 
are expressed as nM H,OZ generated per mg cell protein. 
2.6. Chemicul~ 
L-Isoproterenol, prostaglandins Ez (PGE,), nitroblue tetrazolium 
(NBT). phorbol 12-my&ate 13-acetate (PMA), phenolsulfonphthal- 
em (Phenol red), horseradish peroxidase (type II. salt-free), bovine 
liver catalase (11.000 IU/ml), 3-isobutyl-1-methylxanthme (IBMX), 
cychc adenosine 3’,5’-monophosphate (CAMP) and forskolin were 
purchased from the Sigma Chemical Company (St. Louis, MO). Bo- 
vine serum albumin (fraction V) was from Miles Laboratories 
(Elkhart. IN). Synthetic ovine PACAP- and its derivative PACAP- 
27, comprismg the 27 NH?-terminal amidated residues were synthe- 
Volume 319, number 1,2 FEBS LETTERS March 1993 
THP-1 monocytes 
- 
12 11 10 9 8 
[Peptides] , -log M 
Fig. 1. Adenylate cyclase activation by PACAP-38, VIP and related 
peptides in THP-1 monocytes. Adenylate cyclase was tested after the 
addition of various concentrations of PACAP- (0) and -27 (H), 
vasoactive intestinal peptide, VIP (a), helodennin (o), the peptides 
with NHZ-terminal histidine and C-terminal methionine (PHM, l ), or 
with NH>-terminal histidine and C-terminal vahne (PHV, o) and he- 
lospectin I (A). Results are means f S.E.M. of 48 experiments per- 
formed in duplicate. 
sized by solid-phase techniques, as previously described [14]. Highly 
purified natural porcine VIP and gastric inhibitory peptide (GIP) were 
purchased from Professor V. Mutt (Department of Biochemistry II. 
Karolinska Institute, Stockholm, Sweden). Crystallized porcine glu- 
cagon (Lot 421306) was from the Novo Research Institute (Bagsvaerd, 
Denmark). Oxyntomodulin, glucagon-like peptide-2, human secretin, 
helodermin, helospectin I and II, the human peptides with NH,-termi- 
nal histidine and C-terminal methionine (PHM-27). or with NH,- 
terminal histidine and C-terminal valine (PHV) were from Peninsula 
Laboratories (St. Helens, UK). The human pancreatic growth 
hormone releasing factor hpGRF 140 was a gift from Dr. J. Rivier 
(The Salk Institute for Biological Studies, San Diego, CA). RPMI- 
1640 medium, fetal calf serum and antibiotics were from Flow Labo- 
ratories. All-trans-retinoic acid (RA) was purchased from Aldrich. 
3. RESULTS 
3.1. Effect of VIP. PACAP and related peptides on 
adenylate cyclase activity in THP-1 monocytes 
Basal adenylate cyclase activity in THP-1 monocyte 
membranes was 5 & 1 nmol cAMP/min/mg protein 
(n = 27 experiments). In the absence or presence of so- 
dium fluoride, PACAP or VIP, this activity was linear 
as a function of the membrane protein concentrations 
(0.3-2 pg/ml) during the incubation period considered 
(O-20 min). When THP-1 monocyte membranes were 
incubated for 15 min at 30°C sodium fluoride (lo-’ M), 
forskolin (4 x lo-’ M), and VIP (lo-’ M) raised basal 
adenylate cyclase activity from 5 ? 1 nmol CAMP/mm/ 
mg protein to, respectively, 52 f 4.5, 28 ? 1.2, and 
17 ? 1.2 nmol cAMP/min/mg protein (n = 5-20 experi- 
ments). 
In THP-1 monocytes, VIP and helodermin concen- 
trations ranging from lo-” to lo-’ M raised basal 
adenylate cyclase activity with a potency K, = 1.6 x 10e9 
M (Fig. 1). Maximal stimulation by the two peptides 
resulted in a 5.3-fold increase in this enzyme activity 
over basal levels. The neuropeptides PACAP- and -27 
produced parallel dose-response curves to those of VIP 
and helodermin, and were respectively 50- and 3.2-times 
more potent than VIP in THP-1 membranes. Half-max- 
imal stimulation of adenylate cyclase by PACAP- was 
observed at a K, value of 3.2 x 10-r’ M. The VIP-related 
peptides PHM, PHV and helospectin I produced similar 
rises in adenylate cyclase activity to those produced by 
VIP and helodermin, but at l&40-times higher concen- 
trations. Helospectin II was less potent than helospectin 
I (data not shown). At lo-’ and 10m6 M, human secretin, 
hpGRF, pancreatic glucagon, oxyntomodulin, and 
GLP-2 did not increase basal adenylate cyclase activity. 
At maximally effective concentrations, paired combi- 
nations of PACAP-38, VIP and helodermin did not 
produce any additional increase in this activity. This 
result suggests that the 3 peptides activate the same pool 
of receptor-transducer systems, since they also raised 
adenylate cyclase activity to a similar degree. In con- 
trast, paired combinations of 10e4 M histamine and IO-’ 
M VIP had additive effects on this activity (data not 
shown). 
3.2. Adenylate cyclase activation in retinoic acid-induced 
THP-1 macrophages 
Sodium fluoride induced similar rises in the adenylate 
cyclase activity of THP-1 monocytes and macrophages. 
In the THP-1 monocytes, this activity increased from 
4.25 to 41.2 nmol cAMP/min/mg protein, i.e. 9.7-fold, 
and in the corresponding THP-1 macrophages, from 3.1 
to 37.3 nmol cAMP/min/mg protein, i.e. 12-fold (n = 4). 
As shown in Fig. 2, retinoic acid-induced ifferentiation 
of THP-1 monocytes into THP-1 macrophage-like cells 
was associated with decreased stimulation of adenylate 
cyclase activity by VIP and PACAP- (2.1-fold), as 
compared to the stimulation observed in undifferenti- 
ated THP-1 monocytes, 3.7-fold. These changes in 
adenylate cyclase responsiveness were not accompanied 
by significant variations in the activation constants of 
the CAMP-inducing agent VIP (K, = 1.3 and 2 x 10m9 
M) in THP-1 monocytes and macrophages, respec- 
tively. 
3.3. Effects of adenylate cyclase activators on H20, for- 
mation 
Under basal conditions, H20, formation was unde- 
tectable in both THP-1 monocytes and the THP-1 mac- 
rophage-like cells induced by retinoic acid. In contrast, 
PMA-stimulated THP- 1 macrophages produced 15.2 
pmol H,O,/h/mg cell protein during the 60 min incuba- 
tion period (n = 51). This amount of H202 was similar 
to that spontaneously released by normal human alveo- 
lar macrophages after 30-60 min incubation, i.e. 10.3 to 
16.1 pmol H,OJh/mg cell protein [8]. The PKC activa- 
tor PMA was ineffective in inducing H,Oz production 
in THP-I monocytes. The CAMP-inducing agents. fors- 
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Fig. 2. Effect of the retinoic acid-induced lfferentiatlon of THP-1 
monocytes mto macrophages on adenylate cyclase activation by VIP. 
The effect of VIP on adenylate cyclase activity was tested on the same 
populations of THP-1 cells, cultured in the presence or absence of 
retinoic acid. Less than 5% of the THP-1 monocytes (closed symbols) 
reduced NBT, compared to 85% of the retinoic acid-induced THP-1 
macrophages (open symbols). Results are means ? S.E.M. of 6 sepa- 
rate experiments performed in duplicate. 
kolin and isoproterenol, inhibited PMA-induced H20Z 
production in differentiated THP- 1 macrophages. Iso- 
proterenol induced 100% inhibition of oxygen metabo- 
lite formation, with a potency I& of 1.5 x 10e6 M (Fig. 
3, right). However, forskolin only induced partial inhi- 
bition, and the neuropeptides VIP and helodermin had 
no effect on H,O, production in THP-l-derived macro- 
phages (Fig. 3, left). 
Human alveolar macrophages maintained a sponta- 
neous release of hydrogen peroxide (21 + 3.9 pmol 
H,O,/h/mg cell protein, n = 47). PMA, at a concentra- 
tion of 10m6 M, increased this release from 25.8 + 3.8 to 
51 + 4.9 pmol HzO,lh/mg cell protein (n = 16). When 
bronchoalveolar macrophages were challenged with 
1O-6 M VIP, the neuropeptide had no effect on CAMP 
generation, and basal or PMA-induced H20Z forma- 
tion. In contrast, the adenylate cyclase activators, fors- 
kolin and isoproterenol, inhibited the spontaneous re- 
lease of 0; from human alveolar macrophages by 100% 
(Fig. 4) and PGEz produced partial inhibition (75%) 
with a potency (IC,, = 10m7 M PGE, (data not shown). 
The inhibitory potency of isoproterenol was similar on 
superoxide production induced by PMA in THP-1 mac- 
rophages (1.5 x 1O-6 M, Fig. 3), and on the spontaneous 
HZ02 release observed in human bronchoalveolar mac- 
rophages (3.2 x 1O-6 M, Fig. 4). 
3.4. Effects of VIP, PACAP and related peptides on 
CAMP generation in normal human peripheral mon- 
ocytes and their macrophages counterparts 
Monocytes and their cultured macrophage counter- 
parts had respective purity ranges of 90 & 1.4% (n = 15) 
174 
and 84 * 3.6% (n = 7). In these cell fractions, basal 
CAMP levels were 1.7 + 0.3 pmol cAMP/lO” monocytes 
and 2.9 f 0.5 pmol cAMP/106 macrophages (n = 6-8 
experiments). In the peripheral monocytes, the neu- 
ropeptides VIP and PACAP- were equipotent in stim- 
ulating CAMP generation (Fig. 5). Stimulation by each 
of these peptides doubled CAMP production, with a 
potency EC,, = 10m9 M. The VIP analogs we tested in 
purified monocytes displayed similar maximal stimula- 
tion and the following order of potency as regards their 
activation of CAMP production: PACAP-38, 
VIP > PHM, PHV > PACAP-27, hpGRF, secretin. 
Rat GRF was about 30-times more potent in this re- 
spect than human pancreatic GRF (n = 3 experiments. 
data not shown). VIP had no effect on CAMP genera- 
tion in monocyte-derived macrophages. 
4. DISCUSSION 
As far as we know, the present work is the first dem- 
onstration that PACAP is a very potent peptide in stim- 
ulating adenylate cyclase activity in normal and leuke- 
mic human monocytes. In THP-1 monocytes, this en- 
zyme’s activity was stimulated by PACAP- concen- 
trations as low as lo-” M. Half-maximal stimulation 
was observed at a K, value of 3.2 x lo-” M PACAP-38. 
Thus, PACAP- was about 50-times more potent than 
VIP or helodermin in THP-1 cell membranes. Our phar- 
macological study further revealed that the VIP analogs 
tested in THP-1 monocytes stimulated adenylate cyclase 
activity with potencies that corresponded to their ap- 
parent affinities for the PACAP receptors previously 
characterized in brain and pancreas, i.e. PACAP- 
38 > helodermin, VIP > PHM, PHV, helospectin [15]. 
THP-1 macrophages 
[Effecters], -logM 
Fig. 3 Effects of VIP and helodermin on PMA-Induced HzOz forma- 
tion by THP-I macrophages. Comparison with the CAMP-inducmg 
agents forskolin and isoproterenol. THP-1 macrophages were mcu- 
bated for 60 min at 37°C in the presence of PMA, either alone (control 
activation) or combined with different concentrations of helodermin 
or VIP (left, II = 67 experiments), isoproterenol or forskolin (right, 
n = 6-9 experiments). Data are means ? S.E.M. All determmations 
were performed in triplicate. 
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Fig. 4. Effect of the CAMP-inducing agents forskolin and isoprotere- 
no1 on PMA-induced HzOz formation in human bronchoalveolar mac- 
rophages. Macrophages were incubated for 60 min at 37°C in the 
presence of PMA alone (control activation) or combined with different 
concentrations of forskohn (left). or isoproterenol (right). Data are 
means f S.E.M. of 4 experiments. All determinations were performed 
in triplicate. 
Accordingly, secretin was ineffective in this system. In 
normal peripheral monocytes, PACAP and VIP acti- 
vated CAMP production with a similar potency 
EC,, = 10Y9 M (Fig. 5), suggesting that the two peptides 
interact with the same receptor-effecter system. How- 
ever, normal peripheral monocytes showed another 
pharmacological response toward the VIP analogues: 
VIP, PACAP- > PHV, PHM > PACAP-27, hpGRF 
and secretin, suggesting that normal and leukemic mon- 
ocytes may harbor different receptor subtypes encoded 
by distinct VIP/PACAP receptor genes, or alternatively, 
undergo a differential receptor processing from a com- 
mon precursor. The novel neuropeptide PACAP- was 
recently isolated from ovine hypothalamus, and exhib- 
ited a 68% amino acid sequence homology with porcine 
VIP in the NH,-terminal region [14]. The peptidergic 
neurotransmitters VIP, PACAP and PHI/PHM have 
been co-localized in intramural neurones of the intestine 
and respiratory tract [16,17], thus providing a mi- 
croanatomic basis for potential neuroparacrine interac- 
tions between innervations containing VIP or PACAP 
and the mucosal immune cells. 
Spontaneous and retinoic acid-induced differentia- 
tion of normal peripheral monocytes and leukemic 
THP-1 monocytes into macrophages was found to re- 
duce the responsiveness of membrane-bound adenylate 
cyclase to the VIP-related peptides. We previously ob- 
served that differentiation of the human histiocytic lym- 
phoma cell line U-937 into monocyte-like cells by reti- 
noic acid similarly reduced the capacity of mature U- 
937 cells to generate CAMP after stimulation by hista- 
mine, isoproterenol or PGE, [18]. These reduced re- 
sponses of adenylate cyclase seem to be due to the differ- 
entiation process observed in normal and leukemic leu- 
kocytes, since addition of retinoic acid to the myeloid 
leukemia cell lines, THP-1 and HL-60, did not reduce 
the amount of Gsa messenger or protein, but led to a 
fast decrease in the ADP-ribosylation of Gscl [19]. We 
therefore suggest hat in THP-1 macrophages, retinoic 
acid treatment reduced the functional expression of the 
Gscz proteins which couple stimulatory hormone recep- 
tors to adenylate cyclase, or alternatively, increased the 
levels of functional inhibitory Gicl proteins. In the pres- 
ent study, the adenylate cyclase activators forskolin, 
isoproterenol and PGE, were found to inhibit superox- 
ide anion production in THP-1 macrophages and 
human bronchoalveolar macrophages. In contrast, VIP 
and helodermin failed to reduce hydrogen peroxide for- 
mation in human bronchoalveolar macrophages and 
activated THP-1 macrophages. Thus, in normal and 
leukemic human macrophages, the degree to which the 
CAMP-inducing agents inhibit the respiratory burst was 
directly related to their relative efficacy on the adenylate 
cyclase system. 
Our results demonstrate that the VIPergic pathway is 
retained during the neoplastic transformation of the 
human monocytic lineages, as we previously reported in 
other peripheral tissues [19-211. However, leukemic 
THP- 1 monocytes display a PACAP-preferring recep- 
tor-adenylate cyclase system, while the peptidergic re- 
ceptor has similar affinity for VIP and PACAP in nor- 
mal peripheral human monocytes. In view of the general 
action of CAMP and adenylate cyclase activators on cell 
proliferation, migration and inflammatory responses, 
the present study indicates that VIP and its related pep- 
tide, PACAP, may play a physiological role and exert 
direct action on the immune effector cells in the bone 
marrow and peripheral blood. These two neuropeptides 
c peripheral monocytes I 
4w 
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Fig. 5. Effect of VIP, PACAP and related peptides on CAMP genera- 
tion in purified human peripheral monocytes. Peripheral monocytes 
were incubated in the presence of PACAP- (0) or -27 (m), VIP (A), 
PHM (o), PHV (o), hpGRF (v) or human secretm (A). Data are 
means f S.E.M. of 4-6 experiments performed in duplicate or tripli- 
cate. 
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may also regulate immune and inflammatory responses 
during the early steps of the monocytelmacrophage con- 
version in intestinal and respiratory mucosa [22,23], 
while terminal differentiation of this cell lineages altered 
their responses, in terms of adenylate cyclase activation 
and regulation of hydrogen peroxide formation. 
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